Pure Extracts and Psyence Form Joint Venture Corporation Pure Psyence

Article

Pure Psyence, Pure Extracts and Psyence’s joint venture company, will develop psilocybin-derived treatments.

Pure Extracts, a plant-based extraction company, and Psyence Group, a biotechnology company specializing in natural psychedelics, announced the formation of a joint venture company on Sept. 28, 2021. The new company, Pure Psyence, will develop nature-derived psilocybin extracts and advanced psilocybin formulations.

Pure Extracts is known for its full spectrum oil extracts and has experience working with cannabis, hemp, functional mushrooms, and psychoactive mushrooms. Their new partner, Psyence, operates one of the first federally-licensed commercial psilocybin cultivation and production facilities in the world.

Pure Psyence will look to develop long-term mental health treatments in the form of psilocybin products. It will leverage Psyence’s supply of psilocybin mushrooms and Pure Extract’s extraction technologies to produce medicinal mushroom extracts and formulations on a commercial pharmaceutical scale.

“Pure Psyence sits at the intersection of evidence-based science and nature,” said Ben Nikolaevsky, CEO, Pure Extracts, in a company press release. “The researchers, scientists, and physicians at Pure Psyence will now be uniquely positioned to bring psilocybin whole mushroom in measurable pharmaceutical dosages to market; a first.”

Source: Pure Extracts

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Related Content